Qrons Inc. (QRON) Research
Qrons Inc. is a biotechnology firm dedicated to creating innovative medical solutions and advanced technologies to address neurological disorders. The company's pipeline features two key investigational therapies: QS100, a 3D-printable, implantable composite of mesenchymal stem cells (MSCs) and synthetic hydrogel, specifically engineered to treat severe penetrating brain injuries; and QS200, an injectable formulation of the MSC-synthetic hydrogel, intended for concussions and other forms of diffuse axonal damage. Established in 2016, Qrons Inc. is headquartered in Long Island City, New York. The company adopted its current name in August 2017, having previously operated as BioLabMart Inc.
Market snapshot
- Symbol
- QRON
- Price
- $0.01
- Day change
- -0.89%
- Market cap
- $199.8K
- P/E ratio
- -2.75x
- 52-week range
- 0.0111-0.173
- Sector
- Healthcare
- Industry
- Biotechnology
Peer companies
Recent insider activity
- Merfeld Ido — A-Award (325000 shares) on 2022-12-22
- Meer Jonah — A-Award (325000 shares) on 2022-12-22
- Merfeld Ido — A-Award (325000 shares) on 2021-12-22
- Meer Jonah — A-Award (325000 shares) on 2021-12-22
- Merfeld Ido — A-Award (325000 shares) on 2020-12-10
Open Qrons Inc. (QRON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.